VRTX

Vertex is a genuinely high-quality franchise: FY2025 revenue grew to $12.0B (+8.9% YoY), the fifth straight year of growth (from $7.57B in FY2021), at a 34.8% operating margin, 32.9% net margin and 21.2% ROE. The balance sheet is a fortress — $18.7B equity against just $6.98B liabilities (0.37x), with $12.3B in total cash and marketable securities per the MD&A — and management is returning capital, buying back $2.02B of stock and shrinking the share count 1.1%. Operating cash flow of $3.63B comfortably funds the ~$5.7B combined R&D/SG&A reinvestment.

But the headline growth is a mirage that should not be extrapolated. Net income's +838% and operating income's +1892% jumps are pure base effects: FY2024's -$536M loss was driven by a one-time $4.4B AIPR&D charge from the Alpine asset acquisition. Normalized earnings have been steady (~$3.3B–$3.95B), and revenue growth is actually decelerating (FY2022 ~18% → FY2025 8.9%). The risk factors are blunt that 'substantially all our net product revenues have been derived from the sale of our CF medicines' — so this remains, today, largely a single-disease story led by TRIKAFTA/KAFTRIO.